Scinai Immunotherapeutics Ltd. filings document foreign private issuer reporting for a Nasdaq-listed ADS issuer operating biopharmaceutical R&D and CDMO businesses. Form 6-K reports furnish current information on material agreements, clinical and regulatory disclosures for PC111 and related immunology programs, Nasdaq minimum bid price notices, capital-structure matters, and incorporation of current reports into Form F-3 and Form S-8 registration statements.
The filing record also documents the completed acquisition of Recipharm Israel Ltd., renamed Scinai Biopharma Services Ltd., including audited subsidiary financial statements and unaudited pro forma consolidated and combined financial information. Proxy and governance filings cover annual general meeting materials, ADS voting procedures, board composition changes, auditor selection, risk factors, and shareholder voting matters.
Scinai Immunotherapeutics Ltd. is registering the resale, after the registration statement becomes effective, of up to 7,587,543 ADSs issuable upon warrant exercise; each ADS represents 40,000 ordinary shares. Selling shareholders receive proceeds from resales, not Scinai. Scinai receives warrant exercise prices only if holders exercise for cash; if all warrants were exercised for cash, gross proceeds would be approximately $6.16 million. Holders are not obligated to exercise, and permitted cashless exercises produce no cash.
Scinai’s CDMO business has a customer agreement with approximately $5.1 million in committed base service fees, subject to performance and contractual termination rights. Services are expected to contribute revenue in 2026 and 2027; potential additional activities remain uncommitted and subject to further agreement and authorization.
The last reported ADS sale price was $0.53 on October 27, 2026, and Scinai reported that the price was again below Nasdaq’s $1.00 minimum bid-price requirement after Nasdaq confirmed the company had regained compliance on September 18, 2026.
Scinai Immunotherapeutics Ltd. said its new CDMO agreement includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. Committed Customer Orders, a supplemental non-GAAP measure, were approximately $8.1 million as of October 20, 2026, versus $1.9 million at year-end 2025, an increase of more than 300%. The measure is neither recognized revenue nor remaining unfulfilled backlog and does not assure future revenue or cash receipts.
The agreement also contemplates approximately $5.85 million in additional clinical manufacturing services in late 2027 and the first half of 2028. This work is uncommitted, excluded from the base commitment and Committed Customer Orders, and requires final scope and pricing plus written activation. Scinai reported approximately $5.3 million in combined net proceeds from recent financings, excluding future proceeds from exercises of newly issued warrants. Management estimates operating runway to late 2027 under current plans; cash receipts from later phases, if activated and delivered, could extend it into the third quarter of 2028, subject to sales, timely collections and successful execution.
Scinai Immunotherapeutics Ltd. (SCNI) closed a private placement and warrant-inducement transaction, receiving approximately $4.0 million in aggregate gross proceeds before placement-agent fees and expenses; this excludes future proceeds from the exercise of newly issued Series A-1 Warrants. The placement involved 2,458,334 ADSs (or pre-funded warrants in lieu), each representing 40,000 ordinary shares, plus Series A-1 Warrants to purchase up to 3,687,501 ADSs. Scinai also closed the immediate exercise of Existing Warrants to purchase up to 879,194 ADSs at $1.20 per ADS and issued New Warrants to purchase up to 1,318,791 ADSs.
Scinai intends to use net proceeds and existing cash to advance current customer programs, pursue additional CDMO contracts and selectively invest in its immunotherapy pipeline. It estimates an operating runway to late 2027; activation of later CDMO phases and associated cash receipts, after delivery costs, could extend it into 2028. Both estimates depend on sales and collection assumptions, timely customer payments and execution, and remain subject to customer termination rights and changes in plans and costs.
The private-placement ADSs and warrants, New Warrants and their underlying securities were unregistered. Scinai agreed to file a resale registration statement for the placement ADSs, ADSs issuable upon exercise of pre-funded and New Warrants, and underlying ordinary shares.
Scinai Immunotherapeutics Ltd. (SCNI) entered into agreements on October 13, 2026, for a private placement involving 2,458,334 ADSs or pre-funded warrants in lieu, plus Series A-1 warrants for up to 3,687,501 ADSs. Each ADS represents 40,000 ordinary shares. The combined price is $1.20 per ADS and accompanying warrants, or $1.1999 per pre-funded warrant; Series A-1 warrants are immediately exercisable at $1.20 for five years.
An inducement agreement provides for immediate cash exercise of existing warrants for 879,194 ADSs at a reduced $1.20 per ADS; the investor is to receive new unregistered warrants for up to 1,318,791 ADSs. Gross proceeds from both transactions are expected to be approximately $4.0 million before fees and expenses, excluding future proceeds from exercising newly issued warrants. Closing is expected on or about October 15, 2026, subject to customary conditions.
Scinai plans to use net proceeds with existing cash for CDMO expansion, customer programs and selective immunotherapy-pipeline investment. It must file a resale registration statement within 15 calendar days of October 15, 2026, and use commercially reasonable efforts to obtain effectiveness within 60 calendar days, or 90 calendar days if the SEC elects review. Warrant exercise is subject to a 4.99% beneficial-ownership cap.
Scinai Immunotherapeutics Ltd. announced that its wholly owned subsidiary entered a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. It includes approximately $5.1 million in committed base service fees, subject to performance and the agreement’s terms, including applicable termination rights. Services are expected to contribute to revenue during 2026 and 2027 as performance obligations are satisfied, with stability services continuing beyond 2027. Advance and milestone payments are expected to support cash flow and working capital during project execution.
Committed Customer Orders across Scinai’s Jerusalem and Yavne operations reached approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025 and more than double the approximately $3.1 million reported as of August 16, 2026. This supplemental measure is not recognized revenue or remaining unfulfilled backlog and does not guarantee future revenue or cash receipts. Potential additional clinical manufacturing carries an indicative, uncommitted service-fee value of $5.85 million for late 2027 through the first half of 2028, subject to final scope and pricing, written authorization, available capacity, and customer development and regulatory progress. It is excluded from the initial commitment and Committed Customer Orders.
Scinai Immunotherapeutics Ltd. registered for resale by YA II PN, Ltd. up to 2,706,450 ADSs, representing 108,258,000,000 ordinary shares, under its standby equity purchase agreement. Scinai receives no proceeds from YA’s resales. Separately, Scinai may sell ADSs to YA, subject to agreement conditions, for up to $15.0 million in aggregate gross proceeds; approximately $1.1 million had been received for 473,275 ADSs issued to YA. The purchase price is 97% of the lowest daily VWAP over three consecutive trading days, subject to a 9.99% beneficial-ownership limit. Scinai states that full issuance would represent approximately 66.67% of total ADSs, based on September 23, 2026 figures.
YA’s commitment ends at the earlier of the 36-month anniversary of September 10, 2025, and YA’s purchase of the full commitment. Scinai says it will focus R&D resources on its NanoAb platform and CDMO business; its licensed IL-17 program remains under evaluation, and the IND submission deadline was extended to November 30, 2026, while the parties negotiate license amendments. Nasdaq confirmed on September 18, 2026 that Scinai regained compliance with the $1.00 minimum bid-price requirement after the August 21, 2026 ADS-ratio change.
Scinai Immunotherapeutics Ltd. (SCNI) reports that it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq notified the company that, for 19 consecutive business days from August 21, 2026 through September 17, 2026, the closing bid price of Scinai’s American Depositary Shares was at or above $1.00, and the prior deficiency matter is now closed.
The company states that, with this listing issue resolved, it remains focused on commercial execution at its Scinai Biopharma Services CDMO business and on advancing its NanoAb immunology therapy programs developed under collaborations with the Max Planck Society and University Medical Center Göttingen.
Scinai Immunotherapeutics Ltd. (SCNI) reports a strategic shift after its option and license arrangements with PinCell for the preclinical program PC111 expired on August 31, 2026 and terminated according to their terms, with no new extension agreed.
Scinai is reallocating R&D resources toward its NanoAb platform and preserving capital and management capacity to support growth of Scinai Biopharma Services, its CDMO business. The company continues a multi-year NanoAb collaboration with the Max Planck Society and University Medical Center Göttingen, including intradermal and systemic IL‑17 programs. The intradermal IL‑17 psoriasis program is the subject of an application under Poland’s FENG program for approximately €12 million in grant funding. On the CDMO side, Scinai reports approximately $3.1 million of Committed Customer Orders as of August 16, 2026 and is pursuing about $5 million of 2026 CDMO revenue, supported by an expanded clinical manufacturing and CMC program for a U.S.-based biopharmaceutical customer under an existing relationship while a broader definitive agreement is negotiated.